Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer

被引：0

作者：

Kohei Nakachi

Masaru Konishi

Masafumi Ikeda

Kazuaki Shimada

Takuji Okusaka

Akio Saiura

Hiroshi Ishii

Masanori Sugiyama

Junji Furuse

Hirohiko Sakamoto

Tomotaka Shimamura

Takehiro Ohta

机构：

[1] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology

[2] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Surgery

[3] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Surgery

[4] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology

[5] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Department of Gastroenterological Surgery

[6] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Department of Gastroenterology

[7] Kyorin University School of Medicine,Department of Surgery

[8] Kyorin University School of Medicine,Department of Medical Oncology

[9] Saitama Cancer Center,Department of Gastroenterological Surgery

[10] Saitama Cancer Center,Department of Gastroenterology

[11] Tokyo Women’s Medical University,Department of Surgery, Institute of Gastroenterology

[12] Otaru General Hospital,undefined

来源：

International Journal of Clinical Oncology | 2018年 / 23卷

关键词：

Biliary tract cancer; Cholangiocarcinoma; S-1; Adjuvant chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：894 / 899

页数：5

共 39 条

[1]

Ishihara S(2016)Biliary tract cancer registry in Japan from 2008 to 2013 J Hepatobiliary Pancreat Sci 23 149-157

[2]

Horiguchi A(2016)Report of the 19th follow-up survey of primary liver cancer in Japan Hepatol Res 46 372-390

[3]

Miyakawa S(2002)Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma Cancer 95 1685-1695

[4]

Kudo M(2012)Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial JAMA 308 147-156

[5]

Izumi N(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[6]

Ichida T(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet 388 248-257

[7]

Takada T(2008)S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study Cancer Chemother Pharmacol 62 849-855

[8]

Amano H(2014)Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study Cancer Chemother Pharmacol 74 699-709

[9]

Yasuda H(2013)Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805) Cancer Sci 104 1211-1216

[10]

Neoptolemos JP(2013)Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer Gastric Cancer 16 133-139

← 1 2 3 4 →